Fortrea Stock Jumps on Barclays Upgrade to Overweight
Shares of clinical research company Fortrea Holdings (FTRE) rose 3.3% in pre-market trading following an upgrade from Barclays. The analyst firm upgraded Fortrea to Overweight from Equal Weight and set a price target of $38, up from $29.
3% in pre-market trading after Barclays upgraded the stock to Overweight from Equal Weight and raised its price target to $38 from $29. Barclays analyst Luke Sergott’s new target implies roughly 23% upside.